Is Climb Bio, Inc. (CLYM) a Buy, Sell, or Hold?
Climb Bio, Inc.
NASDAQ:CLYM
$13.7919 USD
$0.55 (4.17%)
- Volume
- 374.09K
- Average Volume
- 1.19M
- Market Capitalization
- $940.39M
- P/E Ratio
- -17.68
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $14.42
- Year Low
- $1.36
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $27.86
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Aoife Brennan BCh MMSc |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CLYM |
| CUSIP | 28658R106 |
| CIK | 0001768446 |
| Web | https://climbbio.com |
| Phone | 866 857 2596 |
| Currency | USD |
| Employees | 29 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 27.86 |
| Quick Ratio | 27.86 |
| Cash Ratio | 2.05 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.78 |
| Price / Cash Flow | -17.58 |
| Price / Book | 6.35 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $35.00 |
| Low Stock Price Forecast | $17.00 |
| Forecast Upside/Downside | -31.04% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.88 |
| Trailing P/E Ratio | -17.68 |
| PEG Ratio | -0.39 |
| P/E Growth | -0.39 |
| Net Income | $-59.85M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -31.46% |
| Return on Assets | -34.65% |
Financials Score
| AltmanZ Score | 122.56 |
| Piotroski Score | 1.00 |
| Working Capital | 109.33M |
| Total Assets | 152.37M |
| Ebit | -52.79M |
| Market Cap | 897.65M |
| Total Liabilities | 4.29M |
Poll Results
About Climb Bio, Inc. (NASDAQ:CLYM) Stock
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware. ...
Why Is Climb Bio Stock Gaining Friday?
2026-06-12 10:19:28
Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets.
2026-06-11 07:00:00
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an encouraging safety and tolerability profile, robust B-cell depletion, and meaningful platelet responses in heavily pretreated patients.
2026-06-05 07:00:00
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer
2026-05-26 07:00:00
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026.
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
2026-05-21 01:02:36
Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.
2026-05-14 07:00:00
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026.
Climb Bio to Present at Upcoming Investor Conferences
2026-05-12 07:00:00
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-07 07:00:00
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; anticipate data from all ongoing trials in 2026 Secured $110 million private placement led by top-tier healthcare investors WELLESLEY HILLS, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
Frequently Asked Questions
-
What is the current Climb Bio, Inc. (CLYM) stock price?
-
Climb Bio, Inc.(NASDAQ:CLYM) stock price is $13.7919 in the last trading session. During the trading session, CLYM stock reached the peak price of $14.415 while $1.36 was the lowest point it dropped to. The percentage change in CLYM stock occurred in the recent session was 4.17% while the dollar amount for the price change in CLYM stock was $0.55.
-
CLYM's industry and sector of operation?
-
The NASDAQ listed CLYM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLYM?
-
Edgar D. Charles | Chief Medical Officer
Ashley Jones | Senior Vice President of People & Workforce Strategy
Aoife Brennan BCh MMSc | Chief Executive Officer, President & Director
Theresa Donegan | Vice President & Head of Quality
Janaki Subramanyam | Vice President & Head of Regulatory Affairs -
How many employees does CLYM have?
-
Number of CLYM employees currently stands at 29. CLYM operates from PMB #117, 2801 Centerville Road, Wellesley Hills, MA 19808-1609, US.
-
Link for CLYM official website?
-
Official Website of CLYM is: https://climbbio.com
-
How do I contact CLYM?
-
CLYM could be contacted at phone #866 857 2596 and can also be accessed through its website. CLYM operates from PMB #117, 2801 Centerville Road, Wellesley Hills, MA 19808-1609, US.
-
How many shares of CLYM are traded daily?
-
The average number of CLYM shares traded daily for last 3 months was 1.19M.
-
What is the market cap of CLYM currently?
-
The market value of CLYM currently stands at $940.39M with its latest stock price at $13.7919